# Sermorelin FAQ: Mechanism, Half-Life, Safety, and the Record

> Sermorelin questions answered from the research record: what it is, how it works, half-life, comparisons to CJC-1295 and ipamorelin, safety, sleep, IGF-1, and body composition — each cited.

Direct answers to the most-asked sermorelin questions, each carried back to the study or the regulatory record behind it.

## What is sermorelin?

Sermorelin is a synthetic 29-amino-acid peptide — the amidated GHRH(1-29) fragment — corresponding to the amino-terminal 1-29 residues of the 44-amino-acid hypothalamic hormone GHRH, and the shortest fragment that retains full activity at the GHRH receptor [3]. It was previously FDA-approved as a pediatric growth-hormone-deficiency drug (NDA 020443), withdrawn from the US market in 2008 for commercial reasons [5], and is now prepared by compounding pharmacies.

## What does sermorelin do to the body?

Sermorelin binds GHRH receptors on anterior-pituitary somatotrophs and activates the Gs / adenylate cyclase / cAMP / PKA pathway, prompting the pituitary to release the body's own growth hormone in its natural pulsatile pattern; downstream, the liver makes more IGF-1 [3]. Because it acts upstream rather than supplying exogenous growth hormone, somatostatin and IGF-1 negative feedback remain intact [4].

## How does sermorelin compare to CJC-1295?

Both are GHRH-class peptides that stimulate the same receptor, but they differ in how long they last. Native GHRH(1-29) has a very short plasma half-life — about 10-12 minutes IV [3]. CJC-1295 uses a Drug-Affinity-Complex (DAC), a maleimide group that binds serum albumin, to greatly extend its duration. The native peptide's brevity is the documented reason longer-acting analogs were developed.

## How does sermorelin work to stimulate growth hormone production?

Sermorelin engages the GHRH receptor (a class B G-protein-coupled receptor) on pituitary somatotrophs. Receptor activation raises cAMP via adenylate cyclase and activates protein kinase A, increasing GH gene transcription and triggering pulsatile growth hormone release; it also has a trophic effect on somatotrophs [13]. In healthy men, intravenous GHRH(1-29) elicited growth hormone release at doses as low as 0.25 mcg/kg [3].

## Are there other peptides or applications being researched for GHRH analogs?

Yes. A 2025 review surveys GHRH-analog development — both agonists and antagonists — across cancer, regenerative medicine, and metabolic disorders [14], and a 2025 Nature Reviews Endocrinology review synthesizes the broader biology of GHRH and its analogues in health and disease [12]. Stabilized analogs (e.g., tesamorelin; DAC-bearing constructs) are studied alongside native GHRH(1-29).

## Does sermorelin need to be refrigerated?

In the research literature, sermorelin acetate is supplied as a lyophilized (freeze-dried) powder because aqueous peptide solutions are prone to degradation. It is reconstituted with a sterile diluent, and once reconstituted it is typically refrigerated [3]. Compounded preparations are made under USP <797> sterile-compounding standards. This describes laboratory and compounding handling, not self-administration guidance.

## What route was used to administer sermorelin in studies?

Subcutaneous injection is the primary route in the research literature; intravenous dosing was used in diagnostic and pharmacokinetic studies, and an intranasal route was tested historically but showed only about 3-5% bioavailability [3]. These are descriptions of how studies were conducted, not administration instructions for any individual.

## Is sermorelin a steroid?

No. Sermorelin is a 29-amino-acid peptide — the GHRH(1-29) fragment of a hypothalamic hormone — not a steroid. It has no steroid ring structure and does not act on androgen or glucocorticoid receptors. It works by stimulating the pituitary's GHRH receptor to release the body's own growth hormone [3].

## Does sermorelin work?

In its historical approved use, once-daily subcutaneous GHRH(1-29) accelerated linear growth in prepubertal GH-deficient children, raising first-year height velocity from about 4.1 to roughly 7-8 cm/year [1]. In healthy older men, 14 days of subcutaneous GHRH(1-29) produced dose-related rises in 24-hour growth hormone and IGF-1 [2]. Rigorous long-term adult anti-aging efficacy data, however, remain limited.

## How long does it take for sermorelin to work?

Acutely, a single intravenous dose elevates serum growth hormone for roughly 3 hours despite the peptide's rapid clearance [3]. Sustained GH/IGF-1 changes were measured over 14 days in older men [2] and over months in pediatric growth studies [1]. One pediatric continuous-infusion study saw an early growth hormone rise decline by 3-6 months [9]. These are study time-courses, not a personal results timeline.

## Sermorelin vs ipamorelin: what is the difference?

They act on different receptors. Sermorelin is a GHRH analog that stimulates the GHRH receptor on somatotrophs. Ipamorelin belongs to the GHRP class, which acts on the ghrelin / GHS receptor — a distinct pathway. Both ultimately prompt growth hormone release, but through separate mechanisms; the two inputs are additive rather than identical [10].

## What is sermorelin used for?

Its only historical FDA-approved indication was evaluation and treatment of growth-hormone deficiency / short stature in children (brand withdrawn in 2008 for commercial reasons) [5]. Beyond that, GHRH(1-29) and its stabilized analogs have been studied in adult GH-axis aging research, cognition, sleep, and body composition. This site presents that literature; it does not present sermorelin as a medicine to self-administer.

## Does sermorelin actually help with sleep, or is it waking me up instead?

The largest natural growth hormone pulse occurs during slow-wave sleep, which is why GH-axis research interest centers on nighttime physiology — growth hormone is secreted in pulses, especially during slow-wave sleep. Direct controlled sleep-outcome trials for sermorelin specifically are limited in the audited literature, so individual sleep experiences cannot be predicted from the studies summarized here.

## Why was sermorelin studied with bedtime dosing?

The pediatric efficacy study administered GHRH(1-29) subcutaneously at bedtime (30 mcg/kg/day) [1], and the GHRH-analog cognition trial dosed before bedtime [6] — timing that aligns with the body's largest natural growth hormone pulse during slow-wave sleep. This reflects how trials were designed; it is not a dosing recommendation for any individual.

## Does sermorelin burn fat?

The strongest body-composition signal in the audited literature comes from a GHRH analog (tesamorelin) cognition trial in older adults: 20 weeks of daily subcutaneous dosing reduced percent body fat by 7.4% [6]. That is a stabilized-analog result, presented factually — it does not establish a proven fat-loss benefit for native sermorelin, and anti-aging / body-composition marketing for sermorelin outpaces the evidence.

## Is sermorelin effective for weight loss?

Sermorelin is not a weight-loss drug and has no such approved indication. The closest audited evidence is a 7.4% reduction in percent body fat with a GHRH analog over 20 weeks [6] — a body-composition change in a research setting, not validated weight-loss efficacy for sermorelin. The body-composition marketing outpaces the underlying data.

## Does sermorelin affect testosterone?

Sermorelin acts on the growth-hormone axis (GHRH receptor → pituitary growth hormone → IGF-1), not the reproductive axis, and the audited literature does not report it as a testosterone secretagogue. No finding in this site's sources establishes a direct testosterone effect, so any such claim sits outside the evidence summarized here.

## Will sermorelin raise my IGF-1 levels?

In research, raising pulsatile growth hormone leads the liver to produce more IGF-1. In healthy older men, 14 days of subcutaneous GHRH(1-29) increased 24-hour IGF-1, and at the high dose GH/IGF-1 parameters no longer differed from young men [2]. A GHRH analog raised IGF-1 by 117%, kept within the physiologic range, over 20 weeks [6]. These describe study cohorts, not an individual prediction.

## Does sermorelin build muscle?

The audited literature does not include a controlled muscle-hypertrophy endpoint for sermorelin. Its mechanism raises growth hormone and IGF-1, and body-composition research with a GHRH analog showed reduced body fat [6], but no audited study demonstrates muscle-building per se. Claims of muscle gain go beyond the evidence summarized here.

## How does sermorelin differ from direct HGH injections?

Sermorelin acts upstream: it prompts the pituitary to release the body's own growth hormone in pulses, so somatostatin and IGF-1 feedback remain operative. Direct growth hormone supplies the hormone exogenously, bypassing pituitary regulation. A 2006 editorial argued that, as a physiologic secretagogue preserving pulsatile release and feedback, sermorelin may be a more physiologic approach to adult-onset growth hormone insufficiency than recombinant growth hormone [4].

## Does sermorelin affect the brain?

In a randomized, double-blind, placebo-controlled trial of 152 older adults (66 with mild cognitive impairment), 20 weeks of a daily subcutaneous GHRH analog had a favorable effect on cognition (P=0.03; executive function P=0.005) [6]. A separate review frames IGF-1 as a neurotrophic factor and the GH/IGF-1 axis as a candidate target in Alzheimer's, with mixed evidence on GHRH-stimulated growth hormone responses [11].

## Can sermorelin or GHRH improve cognition in older adults?

The key audited evidence is the SMART trial (NCT00257712): in 152 older adults, 20 weeks of a daily subcutaneous GHRH analog (tesamorelin, 1 mg/day before bedtime) had a favorable cognition effect (P=0.03), raised IGF-1 by 117% within the physiologic range, and reduced body fat by 7.4%, with mild adverse events [6]. That is a stabilized-GHRH-analog result — suggestive rather than a proven sermorelin benefit.

---

The sermorelin record charted like an expedition — the GHRH(1-29) signal followed from pituitary to IGF-1, each figure carried back to its study, the body-composition data marked as tesamorelin where it belongs, and the stretch where the adult anti-aging evidence runs out left openly unmapped; no clinic behind the compass and nothing here prescribed, dispensed, or sold.